Myeloid Cell Targeting Cancer Immunotherapy via Localized Gene Delivery with Alphavirus Replicon Particles (VRP) Expressing IL-12
Time: 3:30 pm
day: Conference Day Two
Details:
- VRP containing a saRNA vector were developed to reprogram the immunosuppressive tumor microenvironment in solid tumors.
- In preclinical studies, intratumoral injection of VRP efficiently delivered saRNA expressing IL-12, reduced immunosuppressive cell populations, and increased antigenspecific T cells.
- The safety and efficacy of VLPONC-01 will be assessed in a phase I trial as a neoadjuvant treatment in combination with pembrolizumab
New Data!
New Company!
